UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 7, 2007
CollaGenex Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware | | 0-28308 | | 52-1758016 |
(State or Other Juris-
diction of Incorporation) | | (Commission
File Number) | | (IRS Employer
Identification No.) |
41 University Drive, Newtown, PA | | 18940 |
(Address of Principal Executive Offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (215) 579-7388
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events
CollaGenex Pharmaceuticals, Inc., a Delaware corporation (the “Company”) today announced that it has discontinued treatment of all enrolled patients participating in the 40 mg cohort of its Phase II dose-finding study of incyclinide for the treatment of acne. On May 2, 2007, the Company announced that it had suspended enrollment of new patients in this cohort pending investigation of apparent significant photo-toxicity in one patient. Subsequently, the Company has learned of another case of apparent photo-toxicity and has discontinued treatment of all patients in this cohort. Following further investigation, the Company will meet with the FDA to discuss the ongoing development program for incyclinide.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| COLLAGENEX PHARMACEUTICALS, INC. |
| | |
Date: May 7, 2007 | By: | /s/ Nancy C. Broadbent |
| | Nancy C. Broadbent
Chief Financial Officer
(Principal Financial Officer) |
3
